2.4(1H.3H)-嘧啶二酮 | 4874-13-9

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2.4(1H.3H)-嘧啶二酮
• 中文别名: 2，4（1H，3H）-嘧啶二酮，二氢-1，3-二甲基
• 英文名称: 1,3-dimethyluracil
• 英文别名: 1,3-dimethyldihydropyrimidine-2,4(1H,3H)-dione；1,3-dimethyl-5,6-dihydropyrimidine-2,4-dione；5,6-dihydro-1,3-dimethyluracil；1,3-dimethyl-dihydro-pyrimidine-2,4-dione；1,3-Dimethyl-3,4,5,6-tetrahydro-2-(1H)-pyrimidonone；1,3-Dimethyl-1,3-diazinane-2,4-dione
• CAS: 4874-13-9
• 化学式: C₆H₁₀N₂O₂
• 分子量: 142.158
• InChiKey: BVYOHIBNWMCUSW-UHFFFAOYSA-N

物化性质

• 熔点：
  51-52 °C
• 沸点：
  206.5±23.0 °C(Predicted)
• 密度：
  1.169±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2.4(1H.3H)-嘧啶二酮 在 sodium tetrahydroborate 作用下， 生成 γ-(1,3-Dimethylureido)propanol-1
  参考文献：
  名称：

  Selective photoreductions of nucleic acids and their building stones. VIII. Photoreduction and dimerization of 1,3-dimethyluracil

  摘要：

  DOI：

  10.1021/ja01047a015
• 作为产物：
  描述：

  1,3-二甲基脲嘧啶 在 水 、 L-Selectride 作用下， 生成 2.4(1H.3H)-嘧啶二酮
  参考文献：
  名称：

  以三仲丁基硼氢化锂为还原剂的正嵌段二氢尿嘧啶和二氢乳清酸衍生物的新合成

  摘要：

  用三仲丁基硼氢化锂将1，3-二-N-取代的尿嘧啶及其衍生物还原成相应的5，6-二氢化合物，产率极高。尿嘧啶5-位的烷基化也很方便地完成。

  DOI：

  10.1016/s0040-4039(01)83925-3

文献信息

• Nitrogenous heterocyclic compounds and medical use thereof
  申请人：Takahashi Kanji

  公开号：US20070010529A1

  公开（公告）日：2007-01-11

  The present invention relates to a compound represented by formula (I): (wherein all the symbols have the same meanings as defined in the above description) and a production method and use thereof. The compounds represented by formula (I), or its salt, N-oxide or solvate, or a prodrug thereof have p38 MAP kinase inhibitory activity, and are useful in the prevention and/or treatment of those diseases that are supposedly caused or deteriorated by abnormal production of cytokines including inflammatory cytokine or chemokine, or by over response thereto, namely cytokine-mediated diseases such as inflammatory diseases, respiratory diseases, cardiovascular disease, central nervous system diseases, and the like.

  本发明涉及一种由以下式表示的化合物：(其中所有符号的含义与上述描述中定义的相同)，以及其生产方法和用途。由式(I)表示的化合物，或其盐、N-氧化物或溶剂合物，或其前药，在p38 MAP激酶抑制活性方面具有作用，并且在预防和/或治疗那些据称由细胞因子异常产生或恶化引起，或由过度反应引起的疾病方面有用，即细胞因子介导的疾病，如炎症性疾病、呼吸系统疾病、心血管疾病、中枢神经系统疾病等。
• Formamides as Isocyanate Surrogates: A Mechanistically Driven Approach to the Development of Atom-Efficient, Selective Catalytic Syntheses of Ureas, Carbamates, and Heterocycles
  作者：Jeffrey Bruffaerts、Niklas von Wolff、Yael Diskin-Posner、Yehoshoa Ben-David、David Milstein

  DOI：10.1021/jacs.9b08942

  日期：2019.10.16

  dehydrogenative coupling reactions. The design of these highly atom-efficient procedures was driven by the identification and characterization of the relevant organometallic complexes, uniquely exhibiting the trapping of an isocyanate intermediate. DFT calculations further contributed to shed light on the remarkably orchestrated chain of catalytic events, involving metal-ligand cooperation.

  尽管异氰酸酯具有危险性，但它们仍然是散装和精细化学品合成的关键组成部分。通过用效力较低且易于获得的甲酰胺前体替代它们，我们在此展示了一种替代的机械方法，通过基于钌的钳形复合物催化的无受体脱氢偶联反应选择性地获得广泛的尿素、氨基甲酸酯和杂环。这些高原子效率程序的设计是由相关有机金属配合物的鉴定和表征驱动的，独特地表现出异氰酸酯中间体的捕获。DFT 计算进一步有助于阐明催化事件的精心编排链，涉及金属-配体合作。
• [EN] 3-(4-ETHYNYLPHENYL)HEXAHYDROPYRIMIDIN-2,4-DIONE DERIVATIVES AS MODULATORS OF MGLUR4<br/>[FR] DÉRIVÉS 3-(4-ÉTHYNYLPHÉNYL)HEXAHYDROPYRIMIDINE-2,4-DIONE EN TANT QUE MODULATEURS DE MGLUR4
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016146600A1

  公开（公告）日：2016-09-22

  The present invention relates to compounds of formula I wherein Y is C-R1; R1' is hydrogen, F or Cl; R1 is F or Cl; R2 is hydrogen or lower alkyl; R3 is phenyl, pyridinyl or isothiazolyl, wherein the N atom in the pyridinyl group may be in different positions, optionally substituted by one or two halgen atoms; R4 is hydrogen or lower alkyl; Het is a 5-membered heteroaryl group, containg two or three heteroatoms, selected from N, O or S, optionally substituted by lower alkyl, cycloalkyl, lower alkoxyalkyl, heterocycloalkyl, wherein the hetero-atom is O, or lower alkyl substituted by hydroxy, or is a bicyclic heteroaromatic ring, containing two or three N-heteroatoms selected from the groups (II), (III), (IV) or (V) or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.

  本发明涉及式I的化合物，其中Y为C-R1；R1'为氢、F或Cl；R1为F或Cl；R2为氢或较低的烷基；R3为苯基、吡啶基或异噻唑基，其中吡啶基中的N原子可能在不同位置，可选择地被一个或两个卤素原子取代；R4为氢或较低的烷基；Het为一个含有两个或三个异原子（N、O或S）的5元杂环芳基，可选择地被较低的烷基、环烷基、较低的烷氧基烷基、杂环烷基取代，其中异原子为O，或被羟基取代的较低的烷基，或是一个含有两个或三个N-异原子的双环杂芳环，选择自组（II）、（III）、（IV）或（V）的羟基或是它们的对映体和/或光学异构体和/或立体异构体的药学上可接受的盐或酸加合盐，或者是一个外消旋混合物，或者是其对应的对映体和/或光学异构体和/或立体异构体。这些化合物可用于治疗帕金森病、焦虑、呕吐、强迫症、自闭症、神经保护、癌症、抑郁症和2型糖尿病。
• Palladium-Catalyzed Dehydrogenation/Oxidative Cross-Coupling Sequence of β-Heteroatom-Substituted Ketones
  作者：Youngtaek Moon、Daeil Kwon、Sungwoo Hong

  DOI：10.1002/anie.201206610

  日期：2012.11.5

  Concise and selective: The title one‐pot sequence allows formation of the enone functionality and subsequent cross‐coupling. The process provides access to highly functionalized cyclic enolones and enaminones from readily accessible β‐heteroatom‐substituted cyclic ketones.

  简洁，选择性：标题一锅法序列可形成烯酮功能并随后进行交叉偶联。该方法提供了从容易获得的β-杂原子取代的环酮中获得高度官能化的环状烯酮和烯胺酮的途径。
• Transfer Hydrogenation as a Redox Process in Nucleotides
  作者：Florian Achrainer、Vladimir N. Emel’yanenko、Waled Tantawy、Sergey P. Verevkin、Hendrik Zipse

  DOI：10.1021/jp507855k

  日期：2014.9.4

  the nucleotide bases uracil, thymine, cytosine, adenine, and guanine have been determined. The most easily hydrogenated base is uracil, followed by thymine and cytosine. Comparison of these hydrogenation enthalpies with those of ketones and aldehydes derived from sugar models indicates the possibility of near-thermoneutral hydrogen transfer between uracil and the sugar phosphate backbone in oligonucleotides

  使用理论和实验相结合的策略，已确定了核苷酸碱基尿嘧啶，胸腺嘧啶，胞嘧啶，腺嘌呤和鸟嘌呤的氢化热。最容易氢化的碱基是尿嘧啶，其次是胸腺嘧啶和胞嘧啶。这些氢化焓与糖模型衍生的酮和醛的氢化焓的比较表明，寡核苷酸中尿嘧啶和糖磷酸主链之间存在近乎中性的氢转移。